ERT Announces the Appointment of Eric Schwartz as Chief Legal Officer
News Feb 23, 2011
ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, has announced the appointment of Eric Ian Schwartz as Executive Vice President and Chief Legal Officer effective February 22, 2011.
Mr. Schwartz joins ERT with over 15 years of legal and executive management experience with high growth companies in the healthcare and technology industries. Most recently, Mr. Schwartz was Assistant General Counsel at Johnson & Johnson, where he served on the senior management teams of several of the fastest growing companies within Johnson & Johnson’s medical device and consumer products businesses.
Previously, he was Vice President and General Counsel of Animas Corporation, a public medical devices company, manufacturing and distributing insulin delivery systems for people with diabetes. Animas was acquired by Johnson & Johnson in 2006. Mr. Schwartz also held several positions of increasing responsibility with Cable & Wireless Internet Services, Inc., and its predecessor, Digital Island, Inc.
During his career, he has been responsible for a variety of legal, business development, and general management functions. Mr. Schwartz holds a B.A. and J.D. from the University of Virginia, as well as an MBA from the Wharton School of Business at the University of Pennsylvania.
Joel Morganroth, M.D., Chairman and Interim CEO commented: “We are all pleased that Eric will be joining the executive management team at ERT. In his position as Executive Vice President and Chief Legal Officer, he will be responsible for legal affairs, quality assurance, and regulatory compliance, contracts and proposals, and human resources for the Company. The increased complexity of ERT as a multi-service global company with plans to extend its products and services into adjacent markets makes the addition of a Chief Legal Officer particularly important in achieving the Company’s business plans.”
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE